SG11202004865SA - Anti-cd40 antibody drug conjugates - Google Patents
Anti-cd40 antibody drug conjugatesInfo
- Publication number
- SG11202004865SA SG11202004865SA SG11202004865SA SG11202004865SA SG11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA
- Authority
- SG
- Singapore
- Prior art keywords
- drug conjugates
- antibody drug
- antibody
- conjugates
- drug
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593807P | 2017-12-01 | 2017-12-01 | |
| US201762595045P | 2017-12-05 | 2017-12-05 | |
| PCT/IB2018/059480 WO2019106608A1 (en) | 2017-12-01 | 2018-11-29 | Anti-cd40 antibody drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004865SA true SG11202004865SA (en) | 2020-06-29 |
Family
ID=66663861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004865SA SG11202004865SA (en) | 2017-12-01 | 2018-11-29 | Anti-cd40 antibody drug conjugates |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220265842A1 (en) |
| EP (1) | EP3716982A4 (en) |
| JP (1) | JP2021504430A (en) |
| KR (1) | KR20200095493A (en) |
| CN (1) | CN111465399A (en) |
| AU (1) | AU2018374633A1 (en) |
| BR (1) | BR112020010691A2 (en) |
| CA (1) | CA3081559A1 (en) |
| CL (1) | CL2020001442A1 (en) |
| CR (1) | CR20200285A (en) |
| DO (1) | DOP2020000119A (en) |
| EC (1) | ECSP20034868A (en) |
| IL (1) | IL274650A (en) |
| MX (1) | MX2020005465A (en) |
| PE (1) | PE20201464A1 (en) |
| PH (1) | PH12020550551A1 (en) |
| RU (1) | RU2020117156A (en) |
| SG (1) | SG11202004865SA (en) |
| WO (1) | WO2019106608A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021013174A2 (en) * | 2019-01-11 | 2021-11-03 | Novartis Ag | Anti-cd40 antibodies for use in the treatment of hidradenitis suppurativa |
| WO2022166779A1 (en) * | 2021-02-04 | 2022-08-11 | 上海森辉医药有限公司 | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine |
| AR125079A1 (en) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | CARBOXY-SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS |
| TW202304462A (en) | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | Glucocorticoid receptor agonists |
| WO2022268176A1 (en) * | 2021-06-24 | 2022-12-29 | 江苏先声药业有限公司 | Steroid compound, and pharmaceutical composition thereof and use thereof |
| CN117500816A (en) * | 2021-08-26 | 2024-02-02 | 映恩生物制药（苏州）有限公司 | Steroid and conjugate thereof |
| WO2023040793A1 (en) * | 2021-09-14 | 2023-03-23 | 映恩生物制药（苏州）有限公司 | Anti-inflammatory compound and use thereof |
| TW202412857A (en) * | 2022-06-16 | 2024-04-01 | 美商艾伯維生物醫療股份有限公司 | Anti-cd19 antibody drug conjugates |
| US20240218011A1 (en) | 2022-07-21 | 2024-07-04 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
| WO2024064779A1 (en) * | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
| WO2024140917A1 (en) * | 2022-12-28 | 2024-07-04 | 上海盛迪医药有限公司 | Anti-cd40 antibody-drug conjugate, preparation method therefor and medical use thereof |
| WO2024140903A1 (en) * | 2022-12-28 | 2024-07-04 | 苏州盛迪亚生物医药有限公司 | Composition of cd40-binding molecule and pharmaceutical use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101878221B (en) * | 2007-11-30 | 2014-04-02 | 辉瑞有限公司 | Novel glucocorticoid receptor agonists |
| MX2010007023A (en) * | 2007-12-21 | 2010-09-30 | Schering Corp | C20-c21 substituted glucocorticoid receptor agonists. |
| EP3508500A1 (en) * | 2011-04-29 | 2019-07-10 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| EP3125943A4 (en) * | 2014-04-04 | 2017-12-06 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| BR112017025693A2 (en) * | 2015-05-29 | 2018-08-14 | Abbvie Inc. | anti-cd40 antibodies and their uses |
-
2018
- 2018-11-29 PE PE2020000592A patent/PE20201464A1/en unknown
- 2018-11-29 RU RU2020117156A patent/RU2020117156A/en unknown
- 2018-11-29 JP JP2020529611A patent/JP2021504430A/en not_active Ceased
- 2018-11-29 AU AU2018374633A patent/AU2018374633A1/en not_active Abandoned
- 2018-11-29 CR CR20200285A patent/CR20200285A/en unknown
- 2018-11-29 SG SG11202004865SA patent/SG11202004865SA/en unknown
- 2018-11-29 BR BR112020010691-7A patent/BR112020010691A2/en not_active Application Discontinuation
- 2018-11-29 MX MX2020005465A patent/MX2020005465A/en unknown
- 2018-11-29 CA CA3081559A patent/CA3081559A1/en active Pending
- 2018-11-29 KR KR1020207017805A patent/KR20200095493A/en active IP Right Grant
- 2018-11-29 EP EP18883152.3A patent/EP3716982A4/en not_active Withdrawn
- 2018-11-29 WO PCT/IB2018/059480 patent/WO2019106608A1/en active Application Filing
- 2018-11-29 US US16/768,616 patent/US20220265842A1/en not_active Abandoned
- 2018-11-29 CN CN201880077793.3A patent/CN111465399A/en active Pending
-
2020
- 2020-05-04 PH PH12020550551A patent/PH12020550551A1/en unknown
- 2020-05-13 IL IL274650A patent/IL274650A/en unknown
- 2020-05-29 CL CL2020001442A patent/CL2020001442A1/en unknown
- 2020-06-15 DO DO2020000119A patent/DOP2020000119A/en unknown
- 2020-06-29 EC ECSENADI202034868A patent/ECSP20034868A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019106608A1 (en) | 2019-06-06 |
| CR20200285A (en) | 2020-09-04 |
| US20220265842A1 (en) | 2022-08-25 |
| PE20201464A1 (en) | 2020-12-17 |
| JP2021504430A (en) | 2021-02-15 |
| AU2018374633A1 (en) | 2020-05-21 |
| CA3081559A1 (en) | 2019-06-06 |
| EP3716982A1 (en) | 2020-10-07 |
| KR20200095493A (en) | 2020-08-10 |
| RU2020117156A (en) | 2022-01-04 |
| CL2020001442A1 (en) | 2020-09-11 |
| ECSP20034868A (en) | 2020-08-31 |
| IL274650A (en) | 2020-06-30 |
| DOP2020000119A (en) | 2020-08-31 |
| PH12020550551A1 (en) | 2021-03-22 |
| BR112020010691A2 (en) | 2020-11-10 |
| CN111465399A (en) | 2020-07-28 |
| EP3716982A4 (en) | 2021-08-11 |
| MX2020005465A (en) | 2020-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274650A (en) | Anti-cd40 antibody drug conjugates | |
| IL267003A (en) | Multi-drug antibody drug conjugates | |
| IL291073A (en) | Anti-egfr antibody drug conjugates | |
| IL267834B1 (en) | Anti-ccr7 antibody drug conjugates | |
| HK1247210A1 (en) | Drug conjugates comprising antibodies against claudin 18.2 | |
| IL252015A0 (en) | Antibody drug conjugates | |
| IL247936A0 (en) | Anti-egfr antibodies and antibody drug conjugates | |
| EP3250238A4 (en) | Antibody drug conjugates | |
| HK1232123A1 (en) | Hydrophilic antibody drug conjugates | |
| IL250189A0 (en) | Anti-cdh6 antibody drug conjugates | |
| IL251938A0 (en) | Anti-cs1 antibodies and antibody drug conjugates | |
| IL259651A (en) | Site specific her2 antibody drug conjugates | |
| SG10202002153PA (en) | Glycoengineered antibody drug conjugates | |
| EP3253212A4 (en) | Antibody drug conjugates | |
| IL287938A (en) | Antibody drug conjugates | |
| RS61967B1 (en) | Met antibody drug conjugates | |
| LU92659B1 (en) | Glycooptimized antibody drug conjugates |